Nuclear and cytoplasmic expression of ErbB-4 in prostate cancer

International Journal of Biological Markers

Volumn 22, Issue 3, 2007, Pages 181-185

  Ben Yosef, R ^a   Sarid, D ^a   Vexler, A ^a   Lidawi, G ^a   Inbar, M ^a   Marmor, S ^a   Starr, A ^a   Yaal Hahoshen, N ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Cytoplasmic staining; ErbB 4; Nuclear staining; Prostate cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 4; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PROBABILITY; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN EXPRESSION; SURVIVAL TIME;

EID: 36049051896     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.62     Document Type: Article

References (22)

1. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45.
2. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21: 1232-7.
3. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-64.
4. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20.
5. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12.
6. George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7: 1932-6.
7. Krause DS, Van Etten RA. Mechanisms of disease: tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172-87.
8. Canil CM, Moore, MJ, Winquist E, et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group; J Clin Oncol 2005; 23: 455-60.
9. Ziada A, Barqawi A, Glode LM, et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 2004; 60: 332-7.
10. Lara PN Jr, Chee KG, Longmate J, et al. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 2004; 100: 2125-31.
11. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003; 200: 279-81.
12. Merimsky O, Staroselsky AN, Inbar M, et al. Correlation between c-erb-4 receptor expression and response to gemcitabine-cisplatin chemotherapy in non-small cell lung cancer. Ann Oncol 2001; 12: 1131-7.
13. Merimsky O, Kollender Y, Issakov J, et al. Induction chemotherapy for bone sarcoma in adults: correlation of results with erbB-4 expression. Oncol Rep 2003; 10: 1593-9.
14. Junttila TT, Laato M, Vahlberg T, et al. Identification of patients with transitional cell carcinoma of the bladder over-expressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res 2003; 9: 5346-57.
15. Bowers G, Reardon D, Hewitt T, et al. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human Carcinoma cells. Oncogene 2001; 20: 1388-97.
16. Lyne JC, Melhem MF, Finley GG, et al. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J Sci Am 1997; 3: 21-30.
17. Hernes E, Fossa SD, Berner AA, Otnes B, Nesland JM. Expression of the epidermal growth factor receptor family in prostate Carcinoma before and during androgen independence. Br J Cancer 2004; 90: 449-54.
18. Ni CY, Murphy MP, Golde TE, Carpenter G. gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 2001; 294:2179-81.
19. Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF, Hung MC. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 2005; 65: 338-48.
20. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: 843-8.
21. Roach M 3rd, Marquez C, Yuop HS, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994; 28: 33-7.
22. Kattan MW, Zelefsky MJ, Kupelian PA, et al, Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol 2003; 21: 4568-71.